Cell death pathways as therapeutic targets in rhabdomyosarcoma

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DEATH RECEPTOR; DOXORUBICIN; INHIBITOR OF APOPTOSIS PROTEIN; MELPHALAN; PROTEIN BCL 2; PROTEIN BCL 2 INHIBITOR; PROTEIN INHIBITOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; XZH 5;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG TARGETING; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

EID: 84856372062     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/326210     Document Type: Review

References (47)

1. Lockshin R. A., Zakeri Z., Cell death in health and disease Journal of Cellular and Molecular Medicine 2007 11 6 1214 1224
2. Evan G. I., Vousden K. H., Proliferation, cell cycle and apoptosis in cancer Nature 2001 411 6835 342 348 (Pubitemid 32467043)
3. Lowe S. W., Lin A. W., Apoptosis in cancer Carcinogenesis 2000 21 3 485 495 (Pubitemid 30137934)
4. Hengartner M. O., The biochemistry of apoptosis Nature 2000 407 6805 770 776
5. Fulda S., Tumor resistance to apoptosis International Journal of Cancer 2009 124 3 511 515
6. Dagher R., Helman L., Rhabdomyosarcoma: an overview Oncologist 1999 4 1 34 44 (Pubitemid 29102453)
7. Merlino G., Helman L. J., Rhabdomyosarcomaworking out the pathways Oncogene 1999 18 38 5340 5348
8. Spunt S. L., Smith L. M., Ruymann F. B., Qualman S. J., Donaldson S. S., Rodeberg D. A., Anderson J. R., Crist W. M., Link M. P., Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group Clinical Cancer Research 2004 10 18 I 6072 6079 (Pubitemid 39287511)
9. Crist W. M., Anderson J. R., Meza J. L., Fryer C., Raney R. B., Ruymann F. B., Breneman J., Qualman S. J., Wiener E., Wharam M., Lobe T., Webber B., Maurer H. M., Donaldson S. S., Intergroup Rhabdomyosarcoma Study4: results for patients with nonmetastatic disease Journal of Clinical Oncology 2001 19 12 3091 3102 (Pubitemid 32567502)
10. Ashkenazi A., Targeting the extrinsic apoptosis pathway in cancer Cytokine and Growth Factor Reviews 2008 19 3-4 325 331
11. Saelens X., Festjens N., Vande Walle L., Van Gurp M., Van Loo G., Vandenabeele P., Toxic proteins released from mitochondria in cell death Oncogene 2004 23 16 2861 2874 (Pubitemid 38638848)
12. LaCasse E. C., Mahoney D. J., Cheung H. H., Plenchette S., Baird S., Korneluk R. G., IAP-targeted therapies for cancer Oncogene 2008 27 48 6252 6275
13. Adams J. M., Cory S., The Bcl-2 apoptotic switch in cancer development and therapy Oncogene 2007 26 9 1324 1337 (Pubitemid 46328466)
14. Petak I., Douglas L., Tillman D. M., Vernes R., Houghton J. A., Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis Clinical Cancer Research 2000 6 10 4119 4127
15. Petak I., Vernes R., Szucs K. S., Anozie M., Izeradjene K., Douglas L., Tillman D. M., Phillips D. C., Houghton J. A., A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells Cell Death and Differentiation 2003 10 6 729 739 (Pubitemid 36675734)
16. Izeradjene K., Douglas L., Delaney A. B., Houghton J. A., Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex Cancer Research 2004 64 21 8036 8044 (Pubitemid 39446940)
17. Izeradjene K., Douglas L., Delaney A., Houghton J. A., Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells Clinical Cancer Research 2004 10 19 6650 6660 (Pubitemid 39346562)
18. Fulda S., Kfer M. U., Meyer E., Van Valen F., Dockhorn-Dworniczak B., Debatin K. M., Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer Oncogene 2001 20 41 5865 5877 (Pubitemid 32937956)
19. Takita J., Yang H. W., Bessho F., Hanada R., Yamamoto K., Kidd V., Teitz T., Wei T., Hayashi Y., Absent or reduced expression of the caspase 8 gene occurs frequently in neuroblastoma, but not commonly in Ewing sarcoma or rhabdomyosarcoma Medical and Pediatric Oncology 2000 35 6 541 543
20. Fulda S., Encyclopedia of Cancer Berlin, Germany Springer. Edited by M. Schwab, 2008
21. Yang X., Merchant M. S., Romero M. E., Tsokos M., Wexler L. H., Kontny U., Mackall C. L., Thiele C. J., Induction of caspase 8 by interferon renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB Cancer Research 2003 63 5 1122 1129 (Pubitemid 36278447)
22. Eggert A., Grotzer M. A., Zuzak T. J., Wiewrodt B. R., Ho R., Ikegaki N., Brodeur G. M., Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced Apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression Cancer Research 2001 61 4 1314 1319 (Pubitemid 34292549)
23. Pingoud-Meier C., Lang D., Janss A. J., Rorke L. B., Phillips P. C., Shalaby T., Grotzer M. A., Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma Clinical Cancer Research 2003 9 17 6401 6409 (Pubitemid 38031826)
24. Fulda S., Debatin K. M., IFN sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway Oncogene 2002 21 15 2295 2308 (Pubitemid 34407289)
25. Fulda S., Debatin K. M., 5-Aza-2′-deoxycytidine and IFN- cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8 Oncogene 2006 25 37 5125 5133 (Pubitemid 44285981)
26. Kang Z., Chen J.-J., Yu Y., Li B., Sun S.-Y., Zhang B., Cao L., Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response Clinical Cancer Research 2011 17 10 3181 3192
27. Komdeur R., Meijer C., Van Zweeden M., De Jong S., Wesseling J., Hoekstra H. J., van der Graaf W. T., Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells International Journal of Oncology 2004 25 3 677 684
28. Tomek S., Koestler W., Horak P., Grunt T., Brodowicz T., Pribill I., Halaschek J., Haller G., Wiltschke C., Zielinski C. C., Krainer M., Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines European Journal of Cancer 2003 39 9 1318 1329 (Pubitemid 36579206)
29. Cheong H. J., Lee K. S., Woo I. S., Won J. H., Byun. J. H, Up-regulation of the DR5 expression by proteasome inhibitor MG132 augments TRAIL-induced apoptosis in soft tissue sarcoma cell lines Cancer Research and Treatment 2011 43 124 130
30. Klttermann K., Banning U., Kachel M., Krause C., Krholz D., Mauz-Krholz C., TRAIL-induced cytotoxicity in a melphalan-resistant rhabdomyosarcoma cell line via activation of caspase-2 Anticancer Research 2006 26 1 351 356 (Pubitemid 43206097)
31. Barti-Juhasz H., Mihalik R., Nagy K., Grisendi G., Dominici M., Petak I., Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro Haematologica 2011 96 3 e21 e22
32. Kui S., Rettinger E., Vo B., Weber G., Stais M., Kreyenberg H., Willasch A., Kui Z., Koscielniak E., Klss S., von Laer D., Klingebiel T., Bader P., Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation Haematologica 2010 95 9 1579 1586
33. Margue C. M., Bernasconi M., Barr F. G., Schfer B. W., Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR Oncogene 2000 19 25 2921 2929 (Pubitemid 30389082)
34. Wei C. C., Ball S., Lin L., Liu A., Fuchs J. R., Li P. K., Li C., Lin J., Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells International Journal of Oncology 2011 38 1 279 285
35. Liu A., Liu Y., Xu Z., Yu W., Wang H., Li C., Lin J., Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells Cancer Science 2011 102 7 1381 1387
36. Marini K. D., Payne B. J., Watkins D. N., Martelotto L. G., Mechanisms of Hedgehog signalling in cancer Growth Factors 2011 29 6 221 234
37. Bigelow R. L. H., Chari N. S., Undén A. B., Spurgers K. B., Lee S., Roop D. R., Toftgrd R., McDonnell T. J., Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1 Journal of Biological Chemistry 2004 279 2 1197 1205 (Pubitemid 38082643)
38. Kappler R., Calzada-Wack J., Schnitzbauer U., Koleva M., Herwig A., Piontek G., Graedler F., Adamski J., Heinzmann U., Schlegel J., Hemmerlein B., Quintanilla-Martinez L., Hahn H., Molecular characterization of Patched-associated rhabdomyosarcoma Journal of Pathology 2003 200 3 348 356 (Pubitemid 36827309)
39. Armistead P. M., Salganick J., Roh J. S., Steinert D. M., Patel S., Munsell M., El-Naggar A. K., Benjamin R. S., Zhang W., Trent J. C., Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients Cancer 2007 110 10 2293 2303 (Pubitemid 350100752)
40. McPake C. R., Tillman D. M., Poquette C. A., Olusegen George E., Houghton J. A., Harris L. C., Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status Oncology Research 1998 10 5 235 244 (Pubitemid 128736319)
41. Phillips D. C., Martin S., Doyle B. T., Houghton J. A., Sphingosine-induced apoptosis in rhabdomyosarcoma cell lines is dependent on pre-mitochondrial Bax activation and post-mitochondrial caspases Cancer Research 2007 67 2 756 764 (Pubitemid 46192216)
42. Pazzaglia L., Chiechi A., Conti A., Gamberi G., Magagnoli G., Novello C., Morandi L., Picci P., Mercuri M., Benassi M. S., Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes Histology and Histopathology 2009 24 1 61 67
43. Ramrez-Peinado S., Alczar-Limones F., Lagares-Tena L., El Mjiyad N., Caro-Maldonado A., Tirado O. M., Muoz-Pinedo C., 2-Deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma Cancer Research 2011 71 21 6796 6806
44. Oltersdorf T., Elmore S. W., Shoemaker A. R., Armstrong R. C., Augeri D. J., Belli B. A., Bruncko M., Deckwerth T. L., Dinges J., Hajduk P. J., Joseph M. K., Kitada S., Korsmeyer S. J., Kunzer A. R., Letai A., Li C., Mitten M. J., Nettesheim D. G., Ng S., Nimmer P. M., O'Connor J. M., Oleksijew A., Petros A. M., Reed J. C., Shen W., Tahir S. K., Thompson C. B., Tomaselli K. J., Wang B., Wendt M. D., Zhang H., Fesik S. W., Rosenberg S. H., An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005 435 7042 677 681 (Pubitemid 40825512)
45. Lock R., Carol H., Houghton P. J., Morton C. L., Anders Kolb E., Gorlick R., Patrick Reynolds C., Maris J. M., Keir S. T., Wu J., Smith M. A., Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program Pediatric Blood and Cancer 2008 50 6 1181 1189 (Pubitemid 351555542)
46. Kilic M., Kasperczyk H., Fulda S., Debatin K. M., Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance Oncogene 2007 26 14 2027 2038 (Pubitemid 46514744)
47. Holt S. V., Brookes K. E., Dive C., Makin G. W. J., Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents Oncology Reports 2011 25 4 1177 1181